BioCentury
ARTICLE | Clinical News

IMP321: Ph I TACTI-mel ongoing

April 27, 2017 9:07 PM UTC

An independent DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial evaluating subcutaneous IMP321 every 2 weeks plus Keytruda pembrolizumab. The company will now begin ...